Bocquel Sarah, Soria Angèle, Raison-Peyron Nadia, Badaoui Antoine, Marcant Pierre, Bara Corina, Giordano-Labadie Françoise, Amsler Emmanuelle, Milpied Brigitte, Delaunay Juliette, Darrigade Anne-Sophie, Pralong Pauline, Boulard Claire, Ferrier Le Bouedec Marie-Christine, Tauber Marie, Pasteur Justine, Valois Aude, Le Thuaut Aurélie, Crépy Marie-Noëlle, Bernier Claire
Department of Dermatology, Nantes University Hospital, Nantes, France.
Médecine Sorbonne Université, Service de Dermatologie et d'Allergologie, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP-HP), Dermatology and allergy department, Tenon hospital, AP-HP, Paris, France.
J Am Acad Dermatol. 2024 Mar;90(3):512-520. doi: 10.1016/j.jaad.2023.10.029. Epub 2023 Oct 21.
Limited and conflicting data have been reported on the impact of dupilumab (DUPI) on patch test (PT) results and its efficacy against allergic contact dermatitis (ACD).
This study was undertaken to analyze PT reactivities and relevance during treatment with DUPI to determine whether they could detect ACD in patients with uncontrolled or worsened atopic dermatitis (AD) who were receiving this agent.
This prospective, multicenter study examined 76 DUPI-treated patients who had undergone PTs. The relevant information was collected during 3 visits.
Overall, 36 patients (47%) had ≥1 positive PT reaction, and 142 PT results were positive. Twenty-three patients (30%) had ≥1 positive and clinically relevant PT result. Five of them had clinical eczema improvement after allergen avoidance. We compared the PT results of 36 patients before and during DUPI therapy, representing 1230 paired PT allergens, of which 1022 were the same, 34 were positive, 44 were lost, and 130 were uninterpretable.
Because the number of patients included remains limited, our findings should be confirmed with a larger sample.
Our results confirmed the usefulness of PTs for patients receiving DUPI, with good PT reproducibility. We suggest that all DUPI-treated patients with AD developing partial responses or experiencing symptom worsening should undergo PTs to look for contact sensitization.
关于度普利尤单抗（DUPI）对斑贴试验（PT）结果的影响及其对过敏性接触性皮炎（ACD）的疗效，所报告的数据有限且相互矛盾。
本研究旨在分析接受DUPI治疗期间的PT反应性和相关性，以确定其能否在接受该药物治疗但未得到控制或病情加重的特应性皮炎（AD）患者中检测出ACD。
这项前瞻性、多中心研究对76例接受过PT的DUPI治疗患者进行了检查。在3次就诊期间收集了相关信息。
总体而言，36例患者（47%）有≥1次PT阳性反应，142次PT结果为阳性。23例患者（30%）有≥1次阳性且临床相关的PT结果。其中5例在避免接触过敏原后临床湿疹有所改善。我们比较了36例患者在DUPI治疗前和治疗期间的PT结果，共1230对PT过敏原，其中1022对相同，34对阳性，44对结果缺失，130对结果无法解读。
由于纳入的患者数量仍然有限，我们的研究结果应通过更大规模的样本进行验证。
我们的结果证实了PT对接受DUPI治疗的患者有用，且PT具有良好的可重复性。我们建议，所有接受DUPI治疗且AD病情出现部分缓解或症状加重的患者都应进行PT，以寻找接触性致敏情况。
